IRIS
DE LUCA, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.825
EU - Europa 2.487
AS - Asia 2.474
SA - Sud America 307
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 2
Totale 9.132
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.760
SG - Singapore 928
CN - Cina 804
UA - Ucraina 454
IE - Irlanda 435
GB - Regno Unito 364
TR - Turchia 343
SE - Svezia 289
BR - Brasile 257
DE - Germania 222
IT - Italia 214
FR - Francia 203
VN - Vietnam 144
FI - Finlandia 128
IN - India 111
RU - Federazione Russa 79
CA - Canada 43
PL - Polonia 21
AR - Argentina 20
JP - Giappone 20
HK - Hong Kong 18
KR - Corea 18
CZ - Repubblica Ceca 17
MX - Messico 17
BD - Bangladesh 15
ZA - Sudafrica 15
ID - Indonesia 14
EC - Ecuador 12
ES - Italia 11
IR - Iran 10
BE - Belgio 9
EU - Europa 9
IQ - Iraq 9
LT - Lituania 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 7
CL - Cile 7
AT - Austria 6
IL - Israele 6
KZ - Kazakistan 5
RS - Serbia 5
UZ - Uzbekistan 5
GR - Grecia 4
NL - Olanda 4
UY - Uruguay 4
CO - Colombia 3
EG - Egitto 3
MA - Marocco 3
TN - Tunisia 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
JM - Giamaica 2
NP - Nepal 2
PK - Pakistan 2
RO - Romania 2
SA - Arabia Saudita 2
VE - Venezuela 2
BW - Botswana 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
HN - Honduras 1
IM - Isola di Man 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
MY - Malesia 1
NI - Nicaragua 1
PE - Perù 1
PH - Filippine 1
SR - Suriname 1
TJ - Tagikistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.132
Salva come PNG Salva come JPEG
Città #
Singapore 725
Jacksonville 511
Chandler 508
Dublin 431
Dallas 353
Southend 258
Beijing 215
Ashburn 211
Izmir 192
Princeton 188
Nanjing 151
Wilmington 128
Santa Clara 104
The Dalles 100
Los Angeles 98
Cambridge 84
Dearborn 84
New York 72
Munich 61
Tongling 59
Nanchang 58
Ann Arbor 51
Woodbridge 51
Altamura 45
Buffalo 40
Ho Chi Minh City 38
Chieti 34
Dong Ket 33
Council Bluffs 31
Houston 31
Hefei 30
São Paulo 30
Jiaxing 29
Redondo Beach 26
Boardman 25
Hanoi 25
Shenyang 25
Helsinki 24
Norwalk 24
Tianjin 20
Turku 20
Grevenbroich 19
Kunming 19
Tokyo 19
Warsaw 18
Hong Kong 17
Montreal 17
Seoul 17
Washington 17
Brooklyn 16
Hebei 16
London 16
Frankfurt am Main 15
Stockholm 15
Denver 14
Brno 12
Changsha 12
Hangzhou 12
Johannesburg 12
Leawood 12
San Mateo 12
Toronto 12
San Francisco 11
Ardabil 10
Atlanta 10
Mexico City 10
Nuremberg 10
Phoenix 10
Rio de Janeiro 10
Augusta 9
Cedar Knolls 9
Chicago 9
Jinan 9
Orem 9
Torino 9
Boston 8
Brussels 8
Guangzhou 8
Lanzhou 8
Pescara 8
Poplar 8
Teramo 8
Campobasso 7
Can Tho 7
Chennai 7
Manchester 7
Monmouth Junction 7
Mumbai 7
Ankara 6
Charlotte 6
Falls Church 6
Fribourg 6
Montesilvano Marina 6
Ningbo 6
Rome 6
Belgrade 5
Brasília 5
Changchun 5
Da Nang 5
Hanover 5
Totale 5.832
Salva come PNG Salva come JPEG
Nome #
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 160
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 148
IL 13 in multiple sclerosis 144
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 144
Increasing age at disability milestones among MS patients in the MSBase Registry 137
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 131
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 130
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 125
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 123
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 119
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 119
Effect of TNF intraneural injection into the rat sciatic nerve 118
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 118
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 118
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 117
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 114
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 113
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 113
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 113
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 112
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 112
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 112
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 112
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 112
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 108
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 108
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 107
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 107
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 106
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 106
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 106
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 106
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 105
Effect of rhTNF-alpha injection into rat sciatic nerve 104
JCV-Ab serostatus in MS patients treated with Natalizumab 104
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 104
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 103
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 103
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 101
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 101
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 101
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 100
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 100
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 100
Nail loss after teriflunomide treatment: a new potential adverse event 100
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 100
Interferon beta1b: the Chieti experience 99
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 98
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 97
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 95
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 94
Effect of rhTNF-a injection into rat sciatic nerve 94
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 93
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 92
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 92
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 91
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 90
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 89
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 88
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 86
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 85
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 85
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 84
Mononeuropathy following subcutaneous interferon-β injection 84
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 84
Interferon β 1b: The Chieti experience 83
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 83
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 82
Interferone beta1b: bilancio su un gruppo di 30 pazienti 81
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 81
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 81
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 80
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 79
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 79
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 78
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 78
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 78
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 77
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 76
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 76
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 75
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 74
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 72
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 71
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 69
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 68
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 68
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 68
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 67
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 65
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 62
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 62
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 59
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 57
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 54
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 53
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 52
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 17
Totale 9.269
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.562
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.562
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021401 0 0 0 0 0 123 1 2 80 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/20251.766 117 317 334 26 34 65 42 59 123 94 230 325
2025/20261.869 334 144 500 492 363 36 0 0 0 0 0 0
Totale 9.269